MapLight (MLPT) 10% Owner Catalyst4 Buys 7.33M Shares

What Happened

• Catalyst4, Inc. (reported as a 10% owner of MapLight Therapeutics, MLPT) purchased 4,400,000 shares of MapLight common stock on 2026-08-14 at $11.38 per share for $50,072,000 and acquired derivative instruments (warrants) covering 2,928,686 shares on the same date at an equivalent price basis of $11.38 per share for $33,328,154. The aggregate reported consideration is approximately $83.4 million. The transactions are reported as purchases (code P).

Key Details

• Transaction date: 2026-08-14; filing date: 2026-08-18 (filed within the required two business days).
• Price(s): $11.38 per share for both the open-market/ purchase and the derivative acquisition.
• Shares reported acquired: 4,400,000 common shares; derivative (warrants) covering 2,928,686 shares.
• Shares owned after transaction: Not specified in the filing.
• Notable footnotes from the filing:
  • F1: Shares are held of record by Catalyst4, Inc.; members of Catalyst4’s board (Robert Brown, Ekemini Riley, Mark Vorsatz) share voting/dispositive power but disclaim beneficial ownership of these shares.
  • F2: The warrants are immediately exercisable but may not be exercised to the extent doing so would cause the reporting person to beneficially own more than 49.99% of voting common stock.
  • F3: The warrants do not expire until fully exercised.
• Timeliness: Filing appears timely (filed 2 business days after the transaction).

Context

• This filing reports institutional-level purchases by a 10% stockholder (Catalyst4), not individual insider sales by company executives. For retail investors, purchases by large holders can be informative but do not reveal the holder’s motivation.
• The derivative portion represents warrants that are immediately exercisable subject to ownership caps; they are not automatic conversions and will only increase share count if exercised.